Sergio Harari sul trattamento della linfangioleiomiomatosi (LAM) (in Italian)
0:00
10:40
Il Professor Sergio Harari commenta i risultati di un trial clinico di fase 2 volto a valutare l’attivita’ e la sicurezza del farmaco nintedanib come trattamento in pazienti affetti da linfangioleiomiomatosi (LAM).
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More episodes from "The Lancet Respiratory Medicine in conversation with"
Don't miss an episode of “The Lancet Respiratory Medicine in conversation with” and subscribe to it in the GetPodcast app.